Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.
about
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients.The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials.Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programmeMalignancy rates in patients with rheumatoid arthritis treated with tocilizumab.Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.Certolizumab pegol for the treatment of psoriatic arthritis.Fungal Infections and New Biologic Therapies.Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.Biologics in dermatology: adverse effects.Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study.Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature.One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland
P2860
Q31158500-6CF65DAD-0A4B-48F2-BE99-F9717941C785Q33725553-B175B532-3A6D-48C2-A374-607F0174774AQ34769757-E1620BBA-673C-45E2-95C0-D72385BFBB5FQ35758262-8D965350-0566-4A52-B45C-B0F76CB2BC6EQ36045392-D96C7937-24B7-49C6-8171-CF891AC19383Q36183786-2A6A361F-A6D8-4A6F-B100-0792904C03FDQ36859619-7C1F9B3B-FDB7-4494-BC62-B3BADC9882CBQ36919914-42023C9B-DC3A-4538-AF22-578B7FB798A3Q38219589-BE339F09-A2BB-4AD8-8088-93EF46F98297Q38344194-A69E13A5-5A14-41DE-92D9-6603EB2E58BBQ38794862-8B6FDC6F-4826-46E8-AFB1-9C7B5AD9040BQ38837769-F34AF296-7112-43DF-AA1E-21F4A8301BB6Q38972531-F0A348A5-18B7-47CE-B251-EC9265AD7ECBQ39053105-64A7DC54-6E53-4C81-BCB3-5B6B921019D4Q40169531-F078ED87-E50C-4917-AE75-12E8037D561BQ41120913-941CB6E0-A3CC-4C13-948C-39A55AA997B4Q41931494-48E1DAB0-6AC4-4222-AA1D-7AD797F6BBCDQ42368093-98A3579C-23FF-45F9-88C7-BD7E45F7A0F3Q45951213-F540A780-8B87-4BAC-AF63-299ED8E5BB3BQ47120472-9A1BD2F4-F976-4479-9A8F-B5A567765014Q47836056-9C8AE5E1-E903-4F8C-BAE0-093CE7205A5EQ48140916-818631D1-9B1F-48E2-B62C-13F6850376D7Q49783699-15487EE0-8BCA-42A2-B5E2-0E1A5F45D474Q58800873-C9CD5345-FAB4-4516-9204-0CBC8B4A2976
P2860
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Update on the safety profile o ...... analysis from clinical trials.
@ast
Update on the safety profile o ...... analysis from clinical trials.
@en
Update on the safety profile o ...... analysis from clinical trials.
@nl
type
label
Update on the safety profile o ...... analysis from clinical trials.
@ast
Update on the safety profile o ...... analysis from clinical trials.
@en
Update on the safety profile o ...... analysis from clinical trials.
@nl
prefLabel
Update on the safety profile o ...... analysis from clinical trials.
@ast
Update on the safety profile o ...... analysis from clinical trials.
@en
Update on the safety profile o ...... analysis from clinical trials.
@nl
P2093
P2860
P921
P1476
Update on the safety profile o ...... analysis from clinical trials.
@en
P2093
K Winthrop
L Calabrese
M de Longueville
O Lortholary
V P Bykerk
X Mariette
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-203660
P407
P5008
P577
2013-10-03T00:00:00Z
2015-01-01T00:00:00Z